Biotech Values

[rfj1862]

BTW: Technically, tertiary endpoints can’t be considered statsig unless all secondary endpoints have been met (in hierarchical order). Since REDUCE-IT’s lowest-ranking secondary endpoint—all-cause mortality—was not statsig (a close miss), there is no alpha for any of the tertiary endpoints.

Yes of course! But the critics are using these endpoints far down the list to bash the stock. As I said before, they are really, really digging into a trial that to my mind is an unalloyed success.